Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.
Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim YH, Horinaka M, Sakai T, Utsumi T, Shiotsu S, Takeda T, Katayama R, Takayama K. Katayama Y, et al. Among authors: yamada t. NPJ Precis Oncol. 2023 Jan 26;7(1):12. doi: 10.1038/s41698-023-00350-7. NPJ Precis Oncol. 2023. PMID: 36702855 Free PMC article.
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
Nakao A, Uchino J, Igata F, On R, Ikeda T, Yatsugi H, Hirano R, Sasaki T, Tanimura K, Imabayashi T, Tamiya N, Kaneko Y, Yamada T, Nagata N, Watanabe K, Kishimoto J, Takayama K, Fujita M. Nakao A, et al. Among authors: yamada t. Invest New Drugs. 2018 Oct;36(5):903-910. doi: 10.1007/s10637-018-0617-6. Epub 2018 May 30. Invest New Drugs. 2018. PMID: 29846848 Clinical Trial.
Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment.
Uchino J, Nakao A, Tamiya N, Kaneko Y, Yamada T, Yoshimura K, Fujita M, Takayama K. Uchino J, et al. Among authors: yamada t. Medicine (Baltimore). 2018 Jun;97(23):e11081. doi: 10.1097/MD.0000000000011081. Medicine (Baltimore). 2018. PMID: 29879078 Free PMC article. Clinical Trial.
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer.
Chihara Y, Date K, Takemura Y, Tamiya N, Kohno Y, Imabayashi T, Kaneko Y, Yamada T, Ueda M, Arimoto T, Uchino J, Iwasaki Y, Takayama K. Chihara Y, et al. Among authors: yamada t. Invest New Drugs. 2019 Apr;37(2):291-296. doi: 10.1007/s10637-018-0656-z. Epub 2018 Aug 18. Invest New Drugs. 2019. PMID: 30121935 Clinical Trial.
An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer.
Yoshimura A, Uchino J, Tanimura K, Chihara Y, Tamiya N, Kaneko Y, Takeda T, Hiranuma O, Hasegawa I, Kubota Y, Shiotsu S, Takumi C, Hiraoka N, Yamada T, Takayama K. Yoshimura A, et al. Among authors: yamada t. Medicine (Baltimore). 2018 Oct;97(40):e12660. doi: 10.1097/MD.0000000000012660. Medicine (Baltimore). 2018. PMID: 30290647 Free PMC article.
Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report.
Nishioka N, Yamada T, Harita S, Hirai S, Katayama Y, Nakano T, Okura N, Tamiya N, Kaneko Y, Uchino J, Takayama K. Nishioka N, et al. Among authors: yamada t. Respir Med Case Rep. 2018 Oct 6;25:261-263. doi: 10.1016/j.rmcr.2018.10.004. eCollection 2018. Respir Med Case Rep. 2018. PMID: 30310765 Free PMC article.
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
Yoshimura A, Yamada T, Okura N, Takeda T, Furutani W, Kubota Y, Shiotsu S, Hiranuma O, Nishioka N, Chihara Y, Tamiya N, Kaneko Y, Uchino J, Takayama K. Yoshimura A, et al. Among authors: yamada t. BMC Cancer. 2018 Dec 11;18(1):1241. doi: 10.1186/s12885-018-5153-4. BMC Cancer. 2018. PMID: 30537950 Free PMC article.
A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Yoshimura A, Chihara Y, Date K, Tamiya N, Takemura Y, Imabayashi T, Kaneko Y, Yamada T, Ueda M, Arimoto T, Uchino J, Iwasaki Y, Takayama K. Yoshimura A, et al. Among authors: yamada t. Oncologist. 2019 Apr;24(4):459-e131. doi: 10.1634/theoncologist.2018-0858. Epub 2018 Dec 21. Oncologist. 2019. PMID: 30578309 Free PMC article. Clinical Trial.
12,240 results
You have reached the last available page of results. Please see the User Guide for more information.